Eli Lilly and Company (NYSE:LLY) Stock Acquired Sen. Sheldon Whitehouse

Senator Sheldon Whitehouse (D-Rhode Island) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on November 07th, the Senator disclosed that they had bought between $15,001 and $50,000 in Eli Lilly and Company stock on October 30th.

Senator Sheldon Whitehouse also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Starbucks (NASDAQ:SBUX) on 10/29/2024.
• Sold $1,001 – $15,000 in shares of Walt Disney (NYSE:DIS) on 10/29/2024.
• Sold $1,001 – $15,000 in shares of Honeywell International (NASDAQ:HON) on 10/29/2024.
• Sold $1,001 – $15,000 in shares of Mastercard (NYSE:MA) on 10/29/2024.
• Sold $1,001 – $15,000 in shares of Verizon Communications (NYSE:VZ) on 10/29/2024.
• Sold $100,001 – $250,000 in shares of Tesla (NASDAQ:TSLA) on 10/28/2024.
• Sold $15,001 – $50,000 in shares of Tesla (NASDAQ:TSLA) on 10/28/2024.
• Sold $15,001 – $50,000 in shares of Tesla (NASDAQ:TSLA) on 10/11/2024.
• Sold $1,001 – $15,000 in shares of Celsius (NASDAQ:CELH) on 10/8/2024.
• Purchased $1,001 – $15,000 in shares of Coca-Cola (NYSE:KO) on 10/8/2024.

Eli Lilly and Company Price Performance

Shares of LLY opened at $797.58 on Friday. The company has a market capitalization of $757.16 billion, a price-to-earnings ratio of 86.21, a price-to-earnings-growth ratio of 3.05 and a beta of 0.43. The business has a 50-day moving average of $901.75 and a 200-day moving average of $867.32. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.10 earnings per share. As a group, equities research analysts anticipate that Eli Lilly and Company will post 13.21 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.65%. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on LLY shares. Guggenheim lifted their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Deutsche Bank Aktiengesellschaft reduced their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research note on Monday. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a research note on Monday. Finally, Morgan Stanley reissued an “overweight” rating and issued a $1,106.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Four investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $1,008.41.

Institutional Investors Weigh In On Eli Lilly and Company

Several institutional investors have recently bought and sold shares of the stock. Fifth Third Wealth Advisors LLC raised its position in Eli Lilly and Company by 18.5% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 11,593 shares of the company’s stock valued at $10,270,000 after purchasing an additional 1,810 shares during the last quarter. Wrapmanager Inc. increased its position in Eli Lilly and Company by 5.3% during the 3rd quarter. Wrapmanager Inc. now owns 2,551 shares of the company’s stock valued at $2,260,000 after buying an additional 128 shares in the last quarter. BIP Wealth LLC boosted its stake in Eli Lilly and Company by 31.6% during the 3rd quarter. BIP Wealth LLC now owns 988 shares of the company’s stock valued at $875,000 after purchasing an additional 237 shares during the last quarter. Prospera Financial Services Inc boosted its stake in Eli Lilly and Company by 7.1% during the 3rd quarter. Prospera Financial Services Inc now owns 24,629 shares of the company’s stock valued at $21,829,000 after purchasing an additional 1,642 shares during the last quarter. Finally, Meeder Asset Management Inc. boosted its stake in Eli Lilly and Company by 15.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 37,587 shares of the company’s stock valued at $33,300,000 after purchasing an additional 5,167 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

About Senator Whitehouse

Sheldon Whitehouse (Democratic Party) is a member of the U.S. Senate from Rhode Island. He assumed office on January 3, 2007. His current term ends on January 3, 2025. Whitehouse (Democratic Party) is running for re-election to the U.S. Senate to represent Rhode Island. He declared candidacy for the 2024 election. Whitehouse previously served as the Rhode Island attorney general from 1999 to 2003. Before that, he was a United States attorney from 1994 to 1998. He was nominated to the position by President Bill Clinton (D). Whitehouse was a superdelegate to the 2016 Democratic National Convention from Rhode Island. He cast his vote for Hillary Clinton. As of a 2014 analysis of multiple outside rankings, Whitehouse is an average Democratic member of Congress, meaning he will vote with the Democratic Party on the majority of bills.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.